Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction
Rungroj Krittayaphong, Unchalee Permsuwan
Topics & Concepts
MedicineDapagliflozinEjection fractionHeart failureDiabetes mellitusPopulationInternal medicineCost–utility analysisCohortCardiologyCost effectivenessType 2 diabetesEndocrinologyEnvironmental healthRisk analysis (engineering)Diabetes Treatment and ManagementHeart Failure Treatment and ManagementHyperglycemia and glycemic control in critically ill and hospitalized patients